recombinant human rh cripto 1 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
90
Structured Review
R&D Systems
recombinant human rh cripto 1
Recombinant Human Rh Cripto 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+rh+cripto+1/Recombinant+Human+Cripto-1+Protein%2C+CF/pm38150919-133-0-4
Average 90 stars, based on 3 article reviews
Recombinant Human Rh Cripto 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+rh+cripto+1/Recombinant+Human+Cripto-1+Protein%2C+CF/pm38150919-133-0-4
Average 90 stars, based on 3 article reviews
recombinant human rh cripto 1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Recombinant:Article Title: Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1. Article Snippet: In the era of immunotherapy, the targeting of disease-specific biomarkers goes hand in hand with the development of highly selective antibody-based reagents having optimal pharmacological/toxicological profiles.. One interesting and debated biomaker for several types of cancers is the onco-fetal protein Cripto-1 that is selectively expressed in many solid tumours and has been actively investigated as potential theranostic target.. Starting from previously described anti-CFC/Cripto-1 murine monoclonal antibodies, we have moved forward to prepare the humanized recombinant Fabs which have been engineered so as to bear an MTGase site useful for a one-step site-specific labelling. Concentration Assay:Article Title: Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1. Article Snippet: In the era of immunotherapy, the targeting of disease-specific biomarkers goes hand in hand with the development of highly selective antibody-based reagents having optimal pharmacological/toxicological profiles.. One interesting and debated biomaker for several types of cancers is the onco-fetal protein Cripto-1 that is selectively expressed in many solid tumours and has been actively investigated as potential theranostic target.. Starting from previously described anti-CFC/Cripto-1 murine monoclonal antibodies, we have moved forward to prepare the humanized recombinant Fabs which have been engineered so as to bear an MTGase site useful for a one-step site-specific labelling. |